Shots:
- Japan’s MHLW has approved Dupixent to treat COPD in adults whose disease is inadequately controlled with existing therapy
- Approval was based on P-III (BOREAS) trial assessing Dupixent + SoC vs PBO in uncontrolled COPD adults with elevated blood eosinophils, which showed reduced exacerbations & improved lung function; data from BORUS & its replicate P-III (NOTUS) trial were published in The NEJM
- Additionally, Sanofi and Regeneron’s itepekimab is being investigated in 2 P-III trials for COPD
Ref: Regeneron | Image: Sanofi & Regeneron
Related News:- Sanofi Reports the US FDA’s Acceptance & Priority Review of Tolebrutinib for Non-Relapsing Secondary Progressive Multiple Sclerosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
